Ruben Niesvizky, MD

Professor of Medicine
Weill Cornell Medical College
Multiple Myeloma Center and Oncology Operations
New York Presbyterian Hospital/Weill Cornell Medicine
New York, New York

Dr. Ruben Niesvizky received his medical degree from the National Autonomous University of Mexico in Mexico City. He completed his residency in internal medicine and a research fellowship in cell biology/granulomonopoiesis at the National Institute of Medical Sciences and Nutrition in Mexico City. Dr. Niesvizky was awarded a clinical hematology fellowship at Mount Sinai Medical Center, where he was named Chief Fellow. He was also awarded a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center, where he was Assistant Attending Physician. Dr. Niesvizky is currently Director of the Multiple Myeloma Center and the Director of Oncology Operations at New York Presbyterian Hospital/Weill Cornell Medicine. He is also Professor of Medicine at Weill Cornell Medical College, and Attending Physician at New York Presbyterian Hospital.

Dr. Niesvizky is a member of several professional associations, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO). He was director of the clinical core of the Specialized Center of Research (SCOR) of the Leukemia and Lymphoma Society, and is the recipient of various grants and awards from the National Cancer Institute, including translational research grants for the development of new drugs. A frequent lecturer, Dr. Niesvizky regularly presents at annual meetings of ASH and ASCO. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders. His work has been published in peer-reviewed journals such as the New England Journal of Medicine, Blood, Cancer, Leukemia and Lymphoma, and Seminars in Oncology.

Faculty Disclosure
Dr. Ruben Niesvizky has received honoraria related to speakers’ bureau activities from Celgene Corporation, Millennium Pharmaceuticals, Inc., Novartis AG, and Onyx Pharmaceuticals.

Last modified: March 23, 2021